Skip to content
AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study

AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study

Get the podcast

Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT i

The Audio Journal of Oncology

Pan-AKT Inhibitor Tumor Agnostic Targeting was Safe and Effective in Phase One Study

BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor ipatasertib in a phase one study reported at the 2022 EORTC—NCI—AACR symposium on Molecular Targets and Cancer Therapeutics.

Nearly a quarter of the patients treated with the AKT blocker had their tumors shrink. These included patients with breast, endometrial cancer and salivary gland cancers. And tumors remained stable in just over half of the remaining patients.

The first author at the Barcelona symposium, Kevin Kalinsky MD MS, Director of Breast Medical Oncology, Emory University at Winship Cancer Institute, Hematology and Medical Oncology, Atlanta, USA talks with Peter Goodwin.

Tags

akt inhibitiontumor agnostic

Next in EORTC 2022

All 4 interviews

Interview 3 of 4

AUDIO JOURNAL OF ONCOLOGY—MYC-Targeted Drug Had Excellent Safety And Solid Tumor Responses

AUDIO JOURNAL OF ONCOLOGY—MYC-Targeted Drug Had Excellent Safety And Solid Tumor Responses

BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and

2 December 2022
9 min

Related Episodes

AUDIO JOURNAL OF ONCOLOGY – ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy

AUDIO JOURNAL OF ONCOLOGY – ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy

ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy BARCELONA, Spain—Findings from a study of a new investigational therapy targeting the ROS-1 receptor tyrosine

5 Jan 2023
14 min
AUDIO JOURNAL OF ONCOLOGY—Glioma in Adults: Next Generation Sequencing Validates BRAF Targeting

AUDIO JOURNAL OF ONCOLOGY—Glioma in Adults: Next Generation Sequencing Validates BRAF Targeting

BARCELONA, Spain—Next generation sequencing is now an essential part of care for glioma in adults, according to research on BRAF targeting as treatment for this disease reported at the 2022 EORTC-NCI-

7 Nov 2022
9 min